Subscribe
shutterstock_2038005014_wirestock_creators
Wirestock Creators / Shutterstock.com
22 March 2022AmericasMuireann Bolger

Generic Emcure stole COVID-19 vaccine trade secrets, lawsuit claims

US pharma company HDT Bio has accused Emcure Pharmaceuticals of the “blatant theft” of its COVID-19 vaccine technology in a new lawsuit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen takes on Emcure over Sensipar generic
10 September 2018   Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.
Big Pharma
Emcure says court should dismiss COVID vaccine secrets suit
17 May 2022   Indian pharmaceutical company Emcure has asked a Washington court to toss a lawsuit accusing the company of stealing trade secrets related to a COVID-19 vaccine.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Amgen takes on Emcure over Sensipar generic
10 September 2018   Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.
Big Pharma
Emcure says court should dismiss COVID vaccine secrets suit
17 May 2022   Indian pharmaceutical company Emcure has asked a Washington court to toss a lawsuit accusing the company of stealing trade secrets related to a COVID-19 vaccine.

More on this story

Americas
Amgen takes on Emcure over Sensipar generic
10 September 2018   Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.
Big Pharma
Arbutus, Genevant sue Moderna over COVID-19 vaccine tech
1 March 2022   Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.
Big Pharma
Emcure says court should dismiss COVID vaccine secrets suit
17 May 2022   Indian pharmaceutical company Emcure has asked a Washington court to toss a lawsuit accusing the company of stealing trade secrets related to a COVID-19 vaccine.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks